Viagra was originally developed to treat chest pain caused by heart disease. Pfizer scientists synthesized the compound in 1989, hoping it would relax blood vessels in the heart and relieve angina pectoris, a squeezing chest pain that occurs when the heart muscle doesn’t get enough blood flow. The drug worked on blood vessels, just not the ones they were targeting.
The Heart Drug That Wasn’t
Pfizer’s research team created the compound internally known as UK-92,480 as part of an extensive effort to find new treatments for coronary heart disease. The idea was straightforward: the drug would block a specific enzyme (called PDE5) that breaks down a molecule responsible for relaxing blood vessel walls. By blocking that enzyme, the drug would keep blood vessels dilated longer, improving blood flow to the heart and lowering blood pressure.
Early clinical trials in the early 1990s tested this theory in patients with stable angina. The results were underwhelming. In one study of eight patients, the drug did lower blood pressure in both the lungs and the rest of the body, and it reduced cardiac output by about 7%. But these effects were modest and inconsistent. The drug simply wasn’t powerful enough as a heart medication to compete with existing treatments. Pfizer’s original cardiovascular ambitions for the compound were fading.
How a Side Effect Changed Everything
During those early heart disease trials, male participants began reporting an unexpected side effect: improved erections. Researchers quickly understood why. The enzyme the drug targets, PDE5, exists throughout the body’s blood vessels, but it’s found in especially high concentrations in the smooth muscle tissue of the penis. By blocking PDE5 there, the drug allowed blood to flow in and stay longer, producing and maintaining erections far more effectively than it ever eased chest pain.
This was more than a curiosity. At the time, there were no oral medications for erectile dysfunction. The existing options were injections directly into the penis or surgically implanted devices. Pfizer pivoted, redesigning their clinical trial program around this new use. The gamble paid off. In March 1998, the FDA approved sildenafil under the brand name Viagra as the first oral treatment for erectile dysfunction. The European Medicines Agency followed with approval in September of the same year.
Why It Works Better Below the Belt
The reason Viagra failed as a heart drug but succeeded for erectile dysfunction comes down to biology. The drug’s mechanism is the same in both cases: it prevents the breakdown of a signaling molecule called cGMP, which tells smooth muscle cells to relax and let blood vessels widen. When nitric oxide is released naturally (during sexual arousal, for instance), cGMP levels rise and blood vessels open up. Viagra extends that window by keeping cGMP active longer.
In the heart’s blood vessels, this effect was real but too weak to matter clinically. The concentration of PDE5 in coronary arteries just isn’t high enough for the drug to make a meaningful difference compared to other medications already on the market. In penile tissue, though, PDE5 is the dominant enzyme controlling blood flow. Blocking it there produces a strong, reliable effect. Same drug, same mechanism, vastly different results depending on where in the body you look.
A Return to Its Cardiovascular Roots
The story didn’t end with erectile dysfunction. Sildenafil’s original purpose was treating blood vessel problems, and it eventually found a cardiovascular use after all, just not the one Pfizer initially imagined. In the lungs, PDE5 plays a major role in controlling blood vessel tension. People with pulmonary arterial hypertension have dangerously high blood pressure in the arteries connecting the heart to the lungs, which forces the heart to work harder and gradually weakens it.
Sildenafil relaxes those pulmonary blood vessels by the same cGMP mechanism, reducing the pressure and making it easier for the heart to pump blood through the lungs. The FDA approved it for this condition under a separate brand name, Revatio, at a lower dose than Viagra. It’s now a standard treatment that improves exercise ability and slows disease progression in adults with pulmonary arterial hypertension. Patients prescribed Revatio are specifically warned not to also take Viagra, since both contain the same active ingredient and doubling up could cause a dangerous drop in blood pressure.
From Lab Failure to Cultural Landmark
Viagra’s origin story is one of the most famous examples of serendipity in pharmaceutical history. A compound designed to ease chest pain turned out to be mediocre at that job but transformative for a completely different condition that had no good oral treatment. The pivot from angina to erectile dysfunction wasn’t just a lucky break for Pfizer. It fundamentally changed how millions of people understood and sought help for sexual health, turning a topic that had been largely unspoken into something men could address with a prescription.
The drug also opened the door to an entire class of similar medications that work by the same PDE5-blocking mechanism. And its eventual approval for pulmonary hypertension proved that the original cardiovascular instinct behind the compound wasn’t wrong, just pointed at the wrong set of blood vessels.